India Approves Takeda's Dengue Vaccine, Qdenga, for Use in Children and Adults

Takeda's tetravalent dengue vaccine, Qdenga, has received clearance in India for individuals aged 4 to 60 years. While it offers strong protection against severe dengue and hospitalization, its effectiveness against DENV-3 and DENV-4 serotypes may be lower. India's dengue epidemiology is evolving, with increasing reports of DENV-3 becoming more prominent. Qdenga's approval marks a shift from reactive to preventive control measures, but it is not a silver bullet against dengue.